Early safety check for new drug UCB3101 in healthy volunteers
NCT ID NCT06555601
First seen Nov 01, 2025 · Last updated Jun 18, 2026 · Updated 36 times
Summary
This study was an early, first-in-human trial to see if a single dose of UCB3101 is safe and tolerable in healthy adults aged 18 to 65. Researchers gave either the drug or a placebo and watched for side effects. The study was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
UP0124 1
Edegem, Belgium
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.